Every 10-Q that BLUE BIOFUELS INC (BIOF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIOF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOF filings page.
Blue Biofuels, Inc. is a development-stage renewable fuels technology company focused on its Cellulose-to-Sugar (CTS) process and related biofuel pathways. It has not generated material revenue and remains pre-commercial.
For the six months ended June 30, 2026, the company reported a net loss of $1,414,596 and accumulated deficit of $61,544,958. Operating cash outflow was $687,359. Cash and cash equivalents were only $22,040 at June 30, 2026, with a working capital deficit of $3,341,277 and stockholders’ deficit of $4,058,672. Management states that these conditions, along with continued expected losses, raise substantial doubt about its ability to continue as a going concern.
Total liabilities were $5,379,631, including significant related-party obligations: $2,859,070 of deferred wages and directors’ fees and $1,345,000 of related-party notes, plus related-party and third-party convertible notes. During the first half of 2026, the company raised $702,000 through equity, warrant exercises, and notes, and settled $100,630 of legacy notes with shares, while continuing to invest in CTS commercialization and maintaining extensive option and warrant programs for management and directors.
Blue Biofuels, Inc. reported another pre-revenue quarter for the three months ended March 31, 2026, as it continues developing its Cellulose-to-Sugar (CTS) and sustainable aviation fuel technologies. The company generated no revenue and posted a net loss of $663,801, versus a loss of $243,833 a year earlier, largely because 2025 included $444,970 of DOE grant income.
Operating expenses were $659,498, with general and administrative costs of $274,585 and research and development of $384,913, reflecting ongoing pilot and commercialization work. Cash used in operations was $418,535, leaving only $8,665 in cash at quarter-end.
Total liabilities were $5,246,366 against total assets of $1,309,640, resulting in a stockholders’ deficit of $3,936,726 and a working capital deficit of $3,098,898. Management disclosed substantial doubt about the company’s ability to continue as a going concern, noting accumulated losses of $60,794,163 and dependence on new financing.
Blue Biofuels (BIOF) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $422,547 for the quarter and $1,587,132 for the nine months ended September 30, 2025. The company recognized $420,030 in DOE grant income in the quarter and $865,000 year‑to‑date, which partially offset operating expenses.
Cash was $95,194 and total liabilities were $4,543,537 as of September 30, 2025. Stockholders’ deficit widened to $3,057,336. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern due to recurring losses, limited liquidity, and the need for additional financing.
During 2025 to date, the company raised cash through equity and debt: $435,000 from private placements of common stock and warrants, $185,000 of related‑party notes, and $6,250 from warrant exercises. Shares outstanding were 315,723,332 as of October 23, 2025; this is a baseline figure, not an amount being offered.